Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial

Jyoti Bajpai

doi:10.4103/0971-5851.57667

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2008; 29(04): 24-27
DOI: 10.4103/0971-5851.57667

Original Article

Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial

Jyoti Bajpai

Department of Medical Oncology, BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India

› Institutsangaben

Abstract

als PDF herunterladen

PDF (255 kb)

Referenzen

References
1 Bhutani M, Kumar L, Kochupillai V. Lympho-hemopoietic malignancies in India. Med Oncology 2002;19:141-150
2 Kumar L. Chronic Myelogenous leukemia (CML): An update. Nat Med J India 2006;19:255-63
3 Druker BJ, Guilhot F, O′Brien S, et al. Five year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med. 2006;355:2408-2417.
4 Mauro M, Deininger M. Chronic myeloid leukemia in 2006: a perspective. Hematologica. 2006;91:152-158.
5 Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005:183-187.
6 Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.
7 Guilhot F, Apperley J, Kim D et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007 May 15;109(10):4143- 50.
8 Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007 Jun 15;109(12):5143-50.
9 Tokarski J, Newitt J, Lee F, et al. The crystal structure of Abl kinase with BMS-354825, a dual SRC/ABL kinase inhibitor. Blood. 2004;104:abstract 553
10 Cortes J, Rousselot Ph, Kim D et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-3213
11 Talpaz M,shahNP,Kantarjian H, et al.Dasatinib in imatinib resistant CML and Philadelphia chromosome positive leukemias. NEJM2006:354:2531-41
12 Talpaz M, Apperley J. F., Kim D. W., et al. Dasatinib in patients with AP-CML who are resistant or intolerant to Cmatinib:results of the CA180005 ′START-A′study.Proc Am Soc Clin Oncol 2006:24;343a(Abstract 6526).
13 Coutre S., Martinelli G., Dombret H. , et al . Dasatinib in patients with LB- CMLor Ph +ALL who are imatinib resistant or intolerant:the CA180015 ′START - L′ study. Proc Am Soc Clin Oncol 2006;24:6528.
14 Estrov Z. , O′Brien S., Giles F., et al. Dasatinib, a dual Srcabl inhibitor, is active in Ph +CML following treatment with imatinib and AMN107. Proc Am Soc Clin Oncol 2006;24:344a (abstract 6530)
15 Cortes J. E., Kim D. W., Rosti G., et al. Dasatinib in patients with CML- MBC who are imatinib resistant or intolerant: Results of the CA180006 ′START- B′ study. Proc Am Soc Clin Oncol 2006; 24:6529.
16 Kantarjian H, O′Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007;15;109(8):1556-60